genedrive plc is a pharmacogenetic testing company developing and commercialising a rapid and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Presenters: Dr Gino Miele, Chief Executive Officer, Chief Scientific Officer Gino was appointed Chief Executive Officer on 6th August 2024 and a Director and Chief Scientific Officer on 11th September 2023. He has considerable experience in the development of molecular diagnostic technologies and instrumentation and has been the R&D Director at Genedrive since 2015 and its predecessor Epistem since 2011. Prior to that Gino served as Associate Director for clinical translational genomics at Wyeth and Pfizer. Gino has been a key driver in the development of the genedrive® system and positioning of point of care pharmacogenetic testing in emergency healthcare. Russ Shaw, Chief Financial Officer Russ was appointed Chief Financial Officer on 7th April 2022. He has over 25 years of international experience across multiple sectors including life-sciences, technology and the industrials. Prior to joining Genedrive, he spent 10 years as Finance Director at Driver Group plc, an AIM quoted company operating in the engineering and construction industry. Russ has been CFO of several private companies in recent years and is a qualified Accountant and Treasury professional.
